2021
DOI: 10.1039/d1ra04625j
|View full text |Cite
|
Sign up to set email alerts
|

Non-thermal plasma promotes hair growth by improving the inter-follicular macroenvironment

Abstract: Non-thermal plasma (NTP) is widely used in the disinfection and surface modification of biomaterials.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 72 publications
0
4
0
Order By: Relevance
“…One of the four basic states of matter is plasma, which has been extensively employed to clean and alter the surface of biomaterials. According to reports, NTP has the potential to be used clinically in the treatment of skin pathologies such as pressure ulcers, acne, and chronic wounds [30][31][32].…”
Section: Non-thermal Plasma (Ntp) Therapy In Alopeciamentioning
confidence: 99%
See 2 more Smart Citations
“…One of the four basic states of matter is plasma, which has been extensively employed to clean and alter the surface of biomaterials. According to reports, NTP has the potential to be used clinically in the treatment of skin pathologies such as pressure ulcers, acne, and chronic wounds [30][31][32].…”
Section: Non-thermal Plasma (Ntp) Therapy In Alopeciamentioning
confidence: 99%
“…It can, however, heal and improve skin function. In this article, we suggest an air-based NTP therapy that produces extrinsic nitric oxide (eNO) as a preventative measure for the evident loss of hair [ 30 ]. When air-based NTP is applied topically, significant levels of eNO may be immediately measured using a small-sized electrode NO sensing system in the mouse's outer skin, eNO produced by NTP also stimulates hair development by enhancing the formation of capillary tubes and increases cell division, production of hair, and formation of newer blood vessels [ 31 ].…”
Section: Reviewmentioning
confidence: 99%
See 1 more Smart Citation
“… F 52 Dermatomyositis Prednisolone halt Prednisolone; methotrexate 20 mg; 6mg 2014 Dicaro D 9 J Am Acad Dermatol. F 37 Psoriasis Adalimumab Methotrexate N/A 2011 Kim NN 10 Arch Dermatol. F 18 Dermatomyositis N/A Methotrexate N/A F 4 Dermatomyositis N/A Topical corticosteroid N/A F 8 Psoriasis N/A Methylprednisolone; methotrexate; mycophenolate mofetil 30 mg/kg; 25mg/m 2 ; 20 mg/kg, divided every 12 hours 2010 Machado NP 11 Sao Paulo Med J.…”
mentioning
confidence: 99%